Healthcare & Pharmaceuticals

Published by
CorpWatch Blog
|
By |
Three major U.S. medical associations - the American Academy of Family Physicians, the American Academy of Pediatrics and the American College of Cardiology - have bowed to pressure from activist doctors to stop accepting corporate donations from Coca-Cola. The campaigners say Coke exerted undue influence over the medical groups. Read More
Published by
CorpWatch Blog
|
By |
Hundreds of drugs tested in India have been banned from sale in the European Union after French inspectors found flaws in clinical trials conducted by GVK Biosciences, a company based in Hyderabad. The Indian government has threatened to take legal action against the ban under international trade rules. Read More
Published by
CorpWatch Blog
|
By |
Nestle says that it will destroy 400 million packets of Maggi brand instant noodles in India worth some Rs 320 crores ($50.5 million). The company made the announcement after the Food Safety and Standards Authority of India found "hazardous" levels of lead in company products and ordered legal action. Read More
Published by
CorpWatch Blog
|
By |
Actavis, the world's third-largest generic drug manufacturer, has been sued by New York state to prevent it from forcing patients to take a new version of a popular Alzheimer's drug. The company is attempting to hook patients on an extended release version before its U.S. patent expires next year. Read More
Published by
CorpWatch Blog
|
By |
Three major pharmaceutical companies - AstraZeneca, Johnson & Johnson and Pfizer - have recently delayed or canceled clinical trials for testing tuberculosis (TB) drugs in India and South Africa. Activists say this is symbolic of a trend by Big Pharma to abandon research into diseases that affect poor people. Read More
Published by
CorpWatch Blog
|
By |
Bayer, the German pharmaceutical giant, is in hot water after CEO Marijn Dekkers told a Financial Times conference that the company designed medicines "for western patients who can afford it" not for the "Indian market." The company has been critical of the Indian governments efforts to make cheap generic drugs available locally. Read More
* indicates required